Search
Search
Search results 42
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market
Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
Pan Lung Cancer PCR Panel
PRODUCTS
Multi-Gene Mutations Detection Kit
PRODUCTS
KRAS Mutation Detection Kit
PRODUCTS
BRAF V600 Mutations Detection Kit
PRODUCTS
KRAS/NRAS Mutations Detection Kit
PRODUCTS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTS
HANDLE Classic NGS Panel
PRODUCTS
HANDLE HRR NGS Panel
PRODUCTS
Essential NGS Panel
A precise NGS panel, focus on 10 essential genes for clinical targeted therapy.
PRODUCTS
KNB-L1-01 Clinicopathologic features and prognostic value of KRAS, NRAS, and BRAF mutations and DNA mismatch repair status a single-center retrospective study of 1834 Chinese patients with stage I–IV colorectal cancer
DOWNLOAD
KRAS-L2-02 Targeted therapies in colorectal cancer—an integrative view by PPPM
DOWNLOAD
KRAS-L2-01 Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
DOWNLOAD
AmoyDx® KRASNRASBRAF Mutations Detection Kit-P2.2-6T-CE
DOWNLOAD
AmoyDx® KRASNRASBRAF Mutations Detection Kit-P2.1-6T-RUO
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-B2.5-24T-CE
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-B2.4-24T-RUO
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-P2.4-6T-CE
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-P2.3-6T-RUO
DOWNLOAD
KRAS-L1-01 BRAF-L1-02 KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
DOWNLOAD
KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-B2.6-24T-CE
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-B2.5-24T-RUO
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-P3.0-6T-CE
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-P3.0-6T-RUO
DOWNLOAD
Result analysis video-KRAS 19 on ABI7500
Result analysis video-KRAS 19 on ABI7500
Videos
Result analysis video-KRAS 19 on LightCycler 480
Result analysis video-KRAS 19 on LightCycler 480
Videos
Result analysis video-KRAS 19 on Bio-Rad CFX96
Result analysis video-KRAS 19 on Bio-Rad CFX96
Videos
no more...
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
TOKYO and XIAMEN, April 20, 2022 -- Riken Genesis Co., Ltd., (“Rigen Genesis”), Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that in April 2022, AmoyDx® Pan Lung Cancer PCR Panel (the “
News & Events
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
TOKYO and XIAMEN, February 24, 2022 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an application for partial revision of manufacturing and marketing approval for Am
News & Events
AmoyDx Announces Its PLC Panel Adopted as Companion Diagnostic for Brigatinib in Japan
Xiamen, China, January 29, 2022 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company today announced that the AmoyDx Pan Lung Cancer PCR Panel (the “PLC Panel”) has been adopted by Takeda Ph
News & Events
AmoyDx and PREMIA Announce the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan
Xiamen and Hong Kong, January 14, 2022 -- Amoy Diagnostics Co., Ltd., (“AmoyDx”) and PREMIA Holdings (HK) Limited (“PREMIA”) today announced the commercial launch of the AmoyDx® Pan Lung Cancer PCR Panel (the “PLC Panel”) in Japan as a reimbursed companio
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market
Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO® (tepotinib)
TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the
News & Events
AmoyDx® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer
TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”), an i
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
News & Events
no more...
KNB-L1-01 Clinicopathologic features and prognostic value of KRAS, NRAS, and BRAF mutations and DNA mismatch repair status a single-center retrospective study of 1834 Chinese patients with stage I–IV colorectal cancer
DOWNLOAD
KRAS-L2-02 Targeted therapies in colorectal cancer—an integrative view by PPPM
DOWNLOAD
KRAS-L2-01 Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value
DOWNLOAD
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
DOWNLOAD
BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF
DOWNLOAD
AmoyDx® KRASNRASBRAF Mutations Detection Kit-P2.2-6T-CE
DOWNLOAD
AmoyDx® KRASNRASBRAF Mutations Detection Kit-P2.1-6T-RUO
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-B2.5-24T-CE
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-B2.4-24T-RUO
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-P2.4-6T-CE
DOWNLOAD
AmoyDx® KRASNRAS Mutations Detection Kit-P2.3-6T-RUO
DOWNLOAD
KRAS-L1-01 BRAF-L1-02 KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients
DOWNLOAD
KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-B2.6-24T-CE
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-B2.5-24T-RUO
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-P3.0-6T-CE
DOWNLOAD
AmoyDx® KRAS Mutation Detection Kit-P3.0-6T-RUO
DOWNLOAD
no more...
Inquiry
* Required information
Manage your account info
Change your password